CaReMe Forum 19 Oct Pre-meeting Survey

Skip to the content

Dear Doctor, we kindly request your participation in a short pre-meeting survey. This survey will help us ensure that the forum covers relevant topics aligned with your expertise and interests. The survey will only take a few minutes to complete. Thank you for your commitment to this forum, and we look forward to receiving your survey responses.

First Name *

Last Name *

Email Address *

Q1. Within your clinical practice, do you usually perform estimated glomerular filtration rate (eGFR) testing, or albuminuria/proteinuria testing, or both to screen patients for CKD?

Q1. Within your clinical practice, do you usually perform estimated glomerular filtration rate (eGFR) testing, or albuminuria/proteinuria testing, or both to screen patients for CKD?

eGFR testing only
Albuminuria/proteinuria testing only
Both eGFR and albuminuria/proteinuria testing

Q2. How frequently do you typically perform testing for CKD to patient with diabetes?

Q2. At what Hb level do you initiate ESA treatment in NDD (Non-dialysis-dependent) patients with anaemia of CKD, assuming the patient is iron replete?

Never
Less than once a year
Once a year
More than once a year

Q3. How frequently do you typically perform testing for CKD to patients with hypertension?

Q3. How frequently do you typically perform testing for CKD to patients with hypertension?

Never
Less than once a year
Once a year
More than once a year

Q4. To what extent do you agree that albuminuria/proteinuria test is important for identifying kidney damage?

Q4. To what extent do you agree that albuminuria/proteinuria test is important for identifying kidney damage?

Strongly agree
Agree
Neutral
Disagree
Strongly disagree

Q5. When making treatment decisions for patients with CKD, how do you typically utilise eGFR and urine albumin-creatinine ratio (uACR) assessments? Please select all that apply.

Q5. When making treatment decisions for patients with CKD, how do you typically utilise eGFR and urine albumin-creatinine ratio (uACR) assessments? Please select all that apply.

Confirm diagnosis and staging of CKD
Monitor disease progression
Risk stratification to predict the prognosis of CKD
Select appropriate treatment or dose modification
Guidance for lifestyle modifications
Determine the need for referral to a specialist
Develop personalised treatment plans
Other

Other *

Q6. When managing patients with diabetes mellitus and cardiorenal complications in your clinical practice, which of the following treatment approaches do you typically use? Please select all that apply:

Q6. When managing patients with diabetes mellitus and cardiorenal complications in your clinical practice, which of the following treatment approaches do you typically use? Please select all that apply:

Lifestyle modifications (e.g., diet, exercise)
Blood pressure management (e.g., ACE inhibitors, ARBs)
Glycaemic control (e.g., antidiabetic medications)
Medications that provides cardiorenal protection (e.g., SGLT2 inhibitors)
Referral to specialist
Other

Other *

Q7. What are the top 3 challenges that you face when implementing guideline recommendations into your practice?

Q7. What are the top 3 challenges that you face when implementing guideline recommendations into your practice?

Difficulty in navigating and interpreting guideline recommendations
Difficulty in staying current with the latest recommendations
Managing multimorbidity in patients with CKD
Lack of patient awareness for CKD
Limited resources or support for patient adherence
Limited counselling time
Other

Other *

Q8. What other challenges in CKD management would you like the speakers to address during this forum? (optional)

Q8. What other challenges in CKD management would you like the speakers to address during this forum? (optional)

HK-10866 02/10/2024